2019
DOI: 10.1093/annonc/mdz123
|View full text |Cite
|
Sign up to set email alerts
|

Hyperprogressive disease during PD-1/PD-L1 blockade in patients with non-small-cell lung cancer

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

12
252
1
2

Year Published

2019
2019
2024
2024

Publication Types

Select...
8

Relationship

0
8

Authors

Journals

citations
Cited by 232 publications
(267 citation statements)
references
References 25 publications
12
252
1
2
Order By: Relevance
“…Despite striking efficacy in some cases, therapies targeting programmed death 1 (PD-1)/ programmed death ligand 1 (PD-L1) signalling are ineffective at inducing durable responses in a majority of patients and can induce rapidly progressive disease referred to as 'hyperprogression' in a minority of patients. 19,20 A recent study suggests that hyperprogression is in part attributable to blockade of PD-1 signalling on Treg cells which, in susceptible individuals, results in enhanced Treg suppressive function. 21…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…Despite striking efficacy in some cases, therapies targeting programmed death 1 (PD-1)/ programmed death ligand 1 (PD-L1) signalling are ineffective at inducing durable responses in a majority of patients and can induce rapidly progressive disease referred to as 'hyperprogression' in a minority of patients. 19,20 A recent study suggests that hyperprogression is in part attributable to blockade of PD-1 signalling on Treg cells which, in susceptible individuals, results in enhanced Treg suppressive function. 21…”
Section: Discussionmentioning
confidence: 99%
“…Although their immunosuppressive function make Treg cells in themselves an attractive target for specifically directed therapy, it is also important to consider the effects upon Treg cells of conventional immunotherapies thought to primarily target Tconv cells. Despite striking efficacy in some cases, therapies targeting programmed death 1 (PD‐1)/ programmed death ligand 1 (PD‐L1) signalling are ineffective at inducing durable responses in a majority of patients and can induce rapidly progressive disease referred to as ‘hyperprogression’ in a minority of patients . A recent study suggests that hyperprogression is in part attributable to blockade of PD‐1 signalling on Treg cells which, in susceptible individuals, results in enhanced Treg suppressive function .…”
mentioning
confidence: 99%
“…PD-1 blockade facilitated the proliferation of highly suppressive PD-1 + effector (CD4+) T regulatory cells One of three patients with HPD had MDM2 amplification versus 0 of 18 patients without HPD Kim et al [20] TTF <2 months or at least twofold increase of the TGR between pre-immunotherapy and on-treatment (same as [9])…”
Section: Female Gendermentioning
confidence: 99%
“…Reactivation occurs because these antibodies interfere with checkpoints such as programmed death-ligand 1 (PD-L1) and cytotoxic T-lymphocyte-associated antigen 4 that have been exploited by tumor cells to evade the immune response, a necessity if the cancer is going to survive [8]. The FDA approvals notwithstanding, there are now multiple groups that have reported that a minority of patients (albeit encompassing diverse cancers) experience a dramatic acceleration in the rate of tumor progression after starting checkpoint blockade-a phenomenon designated hyperprogressive disease (HPD; Table 1) [9][10][11][12][13][14][15][16][17][18][19][20]. Unfortunately, in the patients who are deemed to have HPD, their median overall survival is estimated to be roughly 3 months [21].…”
mentioning
confidence: 99%
“…The real incidence may be higher, considering that patients who deteriorated fastest could not be fully evaluated. HP was observed in the following types of cancer: non-small-cell lung carcinoma (8%-37%), melanoma (6%-34%), gastrointestinal (15%-21%), head and neck (9-18% and 29% in case of Squamous Cell Carcinoma), gynecological (16%), other lung (10-15%), cutaneous squamous cell carcinoma (9%), renal (5%-7%), colorectal (6%), urothelial (6%) [4,11,[32][33][34][35][36][37][38]. All the discussed studies pertained to PD-1/PD-L1-based immune checkpoint blockade.…”
Section: Hyperprogressionmentioning
confidence: 99%